Crispr Therapeutics Ag (CRSP)

Feb 13, 2025, 11:06 AM EST - 9 days ago

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Feb 11, 2025, 4:01 PM EST - 11 days ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 5, 2025, 4:16 PM EST - 17 days ago

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

Feb 5, 2025, 3:48 PM EST - 17 days ago

Crispr Therapeutics: Why I've Become Even More Bullish (Rating Upgrade)

Jan 15, 2025, 7:20 PM EST - 5 weeks ago

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Jan 14, 2025, 7:39 PM EST - 5 weeks ago

CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 8, 2025, 8:30 AM EST - 6 weeks ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 29, 2024, 12:56 PM EST - 7 weeks ago

Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025

Dec 9, 2024, 12:00 PM EST - 2 months ago

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 20, 2024, 9:28 PM EST - 3 months ago

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

Nov 15, 2024, 11:37 AM EST - 3 months ago

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Nov 14, 2024, 8:30 AM EST - 3 months ago

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 11, 2024, 12:54 PM EST - 3 months ago

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

Nov 5, 2024, 9:01 AM EST - 3 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 6:36 AM EDT - 4 months ago

Crispr Therapeutics: Poised For A Major Turnaround

Oct 6, 2024, 2:00 PM EDT - 4 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY EDIT EXAS NTLA

Sep 18, 2024, 9:11 AM EDT - 5 months ago

Crispr Therapeutics: Prepare To Be Bored

Aug 14, 2024, 6:08 AM EDT - 6 months ago

Crispr's Casgevy Launch: Promising Start, Uncertain Future

Aug 7, 2024, 10:41 AM EDT - 7 months ago

Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential

Aug 5, 2024, 4:01 PM EDT - 7 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jul 7, 2024, 8:30 AM EDT - 8 months ago

Crispr Therapeutics: Beaten Down But Not Broken

Jun 11, 2024, 12:32 PM EDT - 9 months ago

CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript

Jun 10, 2024, 10:27 AM EDT - 9 months ago

Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)

Jun 7, 2024, 6:26 PM EDT - 9 months ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV ENVX GAM HAL LPA PEO

Jun 6, 2024, 12:40 AM EDT - 9 months ago

CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)

May 29, 2024, 8:00 AM EDT - 9 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 24, 2024, 7:40 PM EDT - 9 months ago

Final Trade: UAL, NKE, SLV & CRSP

SLV NKE UAL

May 23, 2024, 8:00 AM EDT - 9 months ago

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

May 15, 2024, 4:12 PM EDT - 10 months ago

CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript)

May 9, 2024, 8:30 AM EDT - 10 months ago

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

May 8, 2024, 4:00 PM EDT - 10 months ago

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 10 months ago

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

May 3, 2024, 11:30 AM EDT - 10 months ago

Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)

Apr 30, 2024, 1:25 PM EDT - 10 months ago

Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics

Apr 24, 2024, 12:40 PM EDT - 10 months ago

Crispr Therapeutics: Now Is The Time To Buy

Apr 22, 2024, 4:30 PM EDT - 10 months ago

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 10, 2024, 3:25 PM EDT - 11 months ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference - (Transcript)

Apr 3, 2024, 8:00 AM EDT - 11 months ago

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 8:00 AM EDT - 11 months ago

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Mar 30, 2024, 3:03 AM EDT - 11 months ago

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

Mar 26, 2024, 2:33 AM EDT - 11 months ago

Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape

Mar 13, 2024, 8:30 AM EDT - 1 year ago

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Mar 1, 2024, 6:21 PM EST - 1 year ago

Final Trade: HPQ, RSG, GM, CRSP

GM HPQ RSG

Feb 29, 2024, 5:02 PM EST - 1 year ago

Crispr Therapeutics CEO: Science in gene editing is moving at break-neck speed

Feb 22, 2024, 12:45 AM EST - 1 year ago

Crispr Therapeutics: Cautiously Optimistic

Feb 21, 2024, 6:04 PM EST - 1 year ago

CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conference (Transcript)

Feb 21, 2024, 7:30 AM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

Feb 13, 2024, 8:30 AM EST - 1 year ago

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

Feb 13, 2024, 2:30 AM EST - 1 year ago

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)